Primary prevention of coronary artery disease

New England Journal of Medicine

Volumn 357, Issue 15, 2007, Pages 1543-1545

  Domanski, Michael J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SERINE PROTEINASE; HYPOCHOLESTEROLEMIC AGENT;

ANAMNESIS; ATHEROSCLEROSIS; CANCER MORTALITY; CHRONIC DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; EDITORIAL; ENVIRONMENTAL FACTOR; FOLLOW UP; HEART INFARCTION; HEREDITY; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NONSENSE MUTATION; NUTRITIONAL ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; BLOOD; HYPERCHOLESTEROLEMIA; NOTE; PRIMARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PRIMARY PREVENTION;

EID: 35248897180     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078183     Document Type: Editorial

References (15)

1. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCaPS. JAMA 1998;279:1615-22.
3. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
4. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86.
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
6. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
7. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003;56:880-90.
8. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in three large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-8.
9. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6.
10. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-82.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med 1988;84:739-49.
13. Vint F. Post-mortem findings in the natives of Kenya. E Afr Med J 1937;13:332-40.
14. Gottmann AW. A report of one hundred three autopsies on Alaskan natives. Arch Pathol 1960;70:117-24.
15. Arthaud JB. Cause of death in 339 Alaskan natives as determined by autopsy. Arch Pathol 1970;90:433-8.